Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

Abroad (travel likely)Recruiting

Conditions

Non Small Cell Lung Cancer · Epidermal Growth Factor Receptor Gene Mutation · Stage III Lung Cancer · Stage IV Lung Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
Study leads
  • Suzanne Cole, MD

    Study Chair

    UT Southwestern Simmons Comprehensive Cancer Center